Leading Health and Life Sciences in Nova Scotia

News Release: IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19

Mar 18, 2020 | IMV Inc., News

See original release here

FOR IMMEDIATE RELEASE

Dartmouth, Nova Scotia, March 18, 2020 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s heritage across its DPX platform technology.

The goal of this development program will be to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. The Company believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.

The Company intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical study: Joanne Langley, M.D. and Scott Halperin, M.D., of the Canadian Center for Vaccinology (CCfV) at Dalhousie University, the Izaak Walton Killam Health Center and the Nova Scotia Health Authority and the Canadian Immunization Research Network (CIRN); along with Dr. Gary Kobinger, Ph.D., Director of the Research Centre on Infectious Diseases at the University Laval in Quebec City and Global Urgent and Advanced Research and Development (GUARD) in Canada. The investigators will assist with preclinical and clinical evaluation and with further development strategy in collaboration with the Canadian government and others.

“As lead investigator on the Phase 1 study of DPX-RSV (Respiratory Syncytial Virus), I witnessed the unique potential of IMV’s epitope-based vaccine approach. I was particularly impressed by the persistence of immunogenicity at one year in an older adult population, suggesting that it is possible with this type of approach, to create an immune response that lasts for an extended period of time” said Dr. Langley. “I believe this collaboration creates the possibility of an accelerated path to clinical development of a vaccine to prevent COVID-19, and underscores the importance of public-private partnerships to tackle this epidemic.”

“We appreciate the urgent need to find solutions to the growing pandemic. Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in sensitive populations. We believe this technology offers a meaningful solution as a potential vaccine, especially in older adults and those with pre-existing conditions who are most at risk to this virus and generally more difficult to vaccinate effectively,” said Frederic Ors, Chief Executive Officer of the Company. “Additionally, we are pleased to be collaborating on this project with Dr. Langley, Dr. Halperin and Dr. Kobinger, who are leading voices in
immunization and infectious disease and share our commitment to public health.”

Third-party research in related coronaviruses has identified the benefit of humoral and cellular (B and T cell) immune responses for protection and resolution of infection, and the Company believes the body of data it has produced to date supports its DPX platform for peptide-based induction of B cells and T cells. The Company is now designing a vaccine candidate against COVID-19 based on third-party immunological studies of SARS-CoV and third-party sequencing data available for SARS-CoV-2 with the goal of selecting potentially immunogenic epitopes within the virus that induce neutralizing antibody responses and protective T cell responses.

Through the Company’s other clinical studies, the Company believes its DPX technology has demonstrated a favorable safety profile and immunogenicity in both cancer and infectious disease settings, with sustained effect and potential for single-dose effectiveness as a prophylactic vaccine. Over 200 patients have been dosed with DPX-based immunotherapies and data from these studies suggest treatment is well-tolerated, including in heavily pre-treated cancer patients with advanced-stage disease. The Company has also applied this technology for the prevention of respiratory syncytial virus (RSV), the second-leading cause of respiratory illness in infants, the elderly and the immunosuppressed. The Company reported its Phase 1 data1 from its clinical candidate, DPX-RSV, which demonstrated a favorable safety profile and immunogenicity in older adults (age 50-64), as well as preclinical data from research-stage candidates aimed at other infectious diseases, including malaria and anthrax.

About the DPX Platform

DPX is the Company’s proprietary lipid-based delivery platform with no aqueous component in the final formulation. The DPX platform can be formulated with peptide antigens. Its unique “no release” mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response within lymph nodes. Fully synthetic, easy to manufacture; each product is stored in dry form and reconstituted in lipids for injection, providing an extended shelf life and simple handling and administration in the clinic. More details about the DPX mechanism of action here: https://imv-inc.com/platform.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform (DPX). This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cellactivating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as in a combination therapy in multiple clinical studies with Merck’s Keytruda®. Connect at www.imv-inc.com.

Cautionary Language Regarding Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forwardlooking statements include, but are not limited to, statements regarding the Company’s intention to develop a DPX-based vaccine candidate against COVID-19, the Company’s belief that the DPX-based platform creates the opportunity for accelerated development and rapid, large-scale production of a COVID-19 vaccine, the Company’s belief in the potential efficacy of its DPXbased vaccine against COVID-19, the Company’s belief in the benefits of the third-party research and studies in related coronavirus and SARS studies and third-party sequencing data and their applicability to the Company’s DPX platform and a DPX platform related vaccine and the Company’s anticipated results from its DPX cancer and infectious disease studies. Such statements should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks and uncertainties affecting the Company and its products. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, the Company’s ability to develop a DPX-based vaccine candidate against the COVID-19 through the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals by the Company to commence and then continue clinical studies, and, if successful, the commercialization of its proposed vaccine candidate related to COVID-19, the Company’s ability to raise sufficient capital to fund such clinical trials and studies and the production of any COVID-19 vaccine, the ultimate applicability of any third-party research and studies in related coronavirus and SARS studies and sequencing, the Company’s ability to enter into agreements with the proposed lead investigators to assist in the clinical development on its vaccine candidate related to COVID-19, the Company’s ability to collaborate with governmental authorities with respect to such clinical development, the coverage and applicability of the Company’s intellectual property rights to any vaccine candidate related to COVID-19, the ability of the Company to manufacture any vaccine candidate related to COVID19 rapidly and at scale and other risks detailed from time to time in the Company’s ongoing filings and in its annual information form filed with the Canadian regulatory authorities on SEDAR as www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec/edgar. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR and on EDGAR.

1: Langley et Al, 2019, Journal of Infectious Diseases

###

Source: IMV Inc.

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819 ext: 1042
M: (514) 617-9481
E: [email protected]

Josh Rappaport, Director, Stern IR
O: (212) 362-1200
E: [email protected]

Media

Delphine Davan, Director, Communications, IMV
M: (514) 968-1046
E: [email protected]

HUDDLE: Local Startups Pitch To Fix N.S. Healthcare

Feb 29, 2020 | News

See original HUDDLE article here

HALIFAX—Dr. Brendan Carr, the president and CEO of the Nova Scotia Health Authority, admits the province’s health care system faces some challenging problems.

Emergency room closures, doctor recruitment, high cancer rates, and a host of other issues are all taxing health care in the province—and Carr believes old solutions won’t fix it.

“We’ve reached a point where simply improving on the way we do things is simply not efficient,” he said Friday, speaking to about 150 health-and-technology-industry players at Volta in Halifax. “We actually need to generate new solutions to these old problems, and we can only do that by bringing new thinking together.”

According to Carr, collaboration and innovation are the keys to fixing health care in the province. And it’s for that exact reason that the NSHA has partnered with several organizations in the province for the “Health Challenge.”

The Health Challenge is a series of events that invite startups to pitch their medical technologies to a panel of judges.

Participants will get 15 minutes to convince the panel their technology can help drive innovation in Nova Scotia health care. There will be five events, each focused on a different provincial health care priority.

Winners of each of the events will receive $100,000 and the opportunity to have their technology adopted for use by the NSHA.

It’s that second part that makes the competition especially valuable for technology startups in the region.

Scott Moffitt is the executive director of BioNova, one of the partners in the Health Challenge. He explained that getting their product into the market is a key step for medical technology companies, but is often one of the toughest hurdles to clear.

“When a [Nova Scotia] company goes to Arkansas and they say ‘is your product being used by the Nova Scotia Health Authority’ and the answer is no, that’s a red flag,” he said.

Moffitt said there are tons of companies in Nova Scotia doing all kinds of innovative things. A real-world endorsement from the NSHA can help put them on the map.

“How do we continue to support and accelerate these companies while adding value to the health care system? That is what today’s is all about. Collaboration is the key. From an ecosystem level it takes a village to support these companies,” he said.

The first of the Health Challenge’s five-pitch competitions will take place on April 8, and will focus on technologies that support cancer care.

For more information on the challenge, or to learn how to apply to pitch, visit the challenge’s website.

News Release: Atlantic Canadian Medtech Companies Invited to Pitch for $100K at Five-Part Health Challenge Events

Feb 28, 2020 | BF2030, News

For Immediate Release:

Atlantic Canadian Medtech Companies Invited to Pitch for $100K at Five-Part Health Challenge Events

HALIFAX, NS (February 28, 2020) – To further drive innovation in the health ecosystem, the Nova Scotia Health Authority, BioNova, the Atlantic Canada Opportunities Agency, QEII Foundation, and Volta, have formed a strategic partnership to present the Health Challenge , a series of five pitch events focusing on specific health care priorities for Nova Scotians.

Each pitch event will focus on a different health care priority, as identified by the Nova Scotia Health Authority. Medtech companies interested in applying must be based in New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador. The winner at each pitch competition will receive $100,000, and their innovative medical technology will be considered for adoption for use by the Nova Scotia Health Authority.

This exciting collaboration between NSHA, BioNova, QEII Health Sciences Centre Foundation, ACOA, and Volta will leverage the organizations’ shared interest in enhancing the health care system.

The first Health Challenge pitch event will focus on medical technologies supporting cancer care, and will take place on Wednesday, April 8, 2020 in downtown Halifax, in Volta’s main event space; members of the public will be welcome to attend. To participate, medtech companies must first apply by email, then be invited to pitch at the Health Challenge Pitch Events. Future pitch topics and application instructions can be found at voltaeffect.com/health-challenge.

Quotes:
“The Health Challenge is meant to stimulate collaboration and engagement with our medtech partners. It will also encourage those of us in the health system to problem solve in a different way and seek innovative health solutions created by Atlantic Canadians – for Atlantic Canadians.
– Dr. Gail Tomblin Murphy, Vice President, Research, Innovation & Discovery and CNE, Nova Scotia Health Authority

“As the leadership organization for the health and life sciences sector in Nova Scotia we strive to build a collaborative ecosystem to realize our full potential. This partnership reflects that and the local adoption of health innovation is a win for our sector, it gives our companies a first customer while keeping patient outcomes and healthcare realities a priority.”
– Scott Moffitt, Executive Director, BioNova

“There are many examples of healthcare innovation taking place within the walls of the QEII Health Sciences Centre – achievements being recognized on the global stage that are helping this community prosper. QEII Foundation donors are at the forefront of bringing some of these major innovations forward, which are not only impacting patient care each and every day but helping solve some of the biggest healthcare challenges like wait times, recruitment and retention, and access to care.”
– Bill Bean, President and CEO, QEII Foundation

“Nova Scotia is home to some of the most exciting medtech companies in Canada, who continue to drive innovation on a global scale. We are excited and proud to partner with the Nova Scotia Health Authority, QEII Foundation, BioNova, and ACOA to provide a platform for these innovators and leaders to elevate health care locally.”
– Jesse Rodgers, CEO, Volta

-30-

About Nova Scotia Health Authority
Nova Scotia Health Authority (NSHA) provides health services to Nova Scotians and a wide array of specialized services to Maritimers and Atlantic Canadians. NSHA operates hospitals, health centres and community-based programs across the province. Our team of health professionals includes employees, doctors, researchers, learners and volunteers. We work in partnership with community groups, schools, governments, foundations and auxiliaries and community health boards.

About BioNova
BioNova leads the development of Health and Life Sciences in Nova Scotia. Our primary mandate is the strategic leadership of the sector to develop economic prosperity.

About QEII Health Sciences Centre Foundation
The QEII Foundation inspires generosity to advance health care at the QEII. With financial support from all levels of the community, the QEII Foundation helps fund new technologies, medical research, innovation and professional education that contribute to life-changing moments experienced every day by patients and their loved ones. By working together with people who share a vision of better health, the Foundation strengthens care delivered at the QEII, improving the health and lives of Atlantic Canadians.

About the Atlantic Canada Opportunities Agency
The Atlantic Canada Opportunities Agency works to create opportunities for economic growth in Atlantic Canada by helping businesses become more competitive, innovative and productive, by working with diverse communities to develop and diversify local economies, and by championing the strengths of Atlantic Canada. Together, with Atlantic Canadians, ACOA is building a stronger economy. For more information, please visit www.acoa-apeca.gc.ca .

About Volta
Volta (formerly Volta Labs) is one of Canada’s largest innovation hubs, located in downtown Halifax, Nova Scotia. Volta is creating a space where members of the Atlantic Canadian innovation ecosystem can work, connect and learn from one another by accessing co-working space, participating in programs and attending events. Volta has been home to more than 50 startups through their Residency program, which have created more than 300 jobs and raised a combined total of $60-million in equity financing.

For more information, contact:
Patti Green, Communications Coordinator, Nova Scotia Health Authority
[email protected], 902-266-6853

Shana Cristoferi, Marketing Manager, BioNova
[email protected] , 902-421-5705

Tanya MacLean, VP Communications and Marketing, QEII Foundation
[email protected] , 902-489-5664

Laurie Snell, Marketing Manager, Volta
[email protected], 902-220-2544

News Release: IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

Feb 25, 2020 | IMV Inc., News

February 25, 2020 at 3:05 AM EST

First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor

79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions

37% achieved durable clinical benefit lasting ≥ 6 months; including four partial regressions so far, overall response rate not yet reached as six patients remain on treatment

Treatment well-tolerated with limited side effects observed

IMV to host a conference call and webcast today, February 25, 2020 at 8:00 a.m. EST; data also to be featured at KOL symposium on Thursday, February 27, 2020

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–Feb. 25, 2020– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today reported updated results from DeCidE1, an ongoing Phase 2 study of its lead candidate, DPX-Survivac, in patients with advanced recurrent ovarian cancer. The new results show that DPX-Survivac immunotherapy is active and well-tolerated in patients with advanced ovarian cancer.

“Today’s update marks a pivotal milestone for IMV and, we believe, is a breakthrough for targeted T cell immunotherapies, as these results demonstrate for the first time activity in a solid tumor which is among the hardest to treat” said Frederic Ors, President and Chief Executive Officer at IMV. “We were pleased to achieve the primary objectives of our DeCidE1 study, showing DPX-Survivac was active, durable and well-tolerated in advanced ovarian cancer. With these results in hand, we plan to engage with the US Food and Drug Administration (FDA) on the design of a potential pivotal trial in ovarian cancer that might support an accelerated pathway.”

Mr. Ors continued, “Notably, these results also continue to validate the unique mechanism of our DPX platform and the relevance of survivin as a cancer target, as we await updated Phase 2 data from two additional studies of DPX-Survivac in the first half of this year.”

“We are highly encouraged by the data from DeCidE1, which shows that DPX-Survivac immunotherapy was well-tolerated and achieved sustained clinical activity in advanced and recurrent ovarian cancer. This is a particularly significant observation in heavily pre-treated patients, for whom remain tremendous unmet need and limited options beyond single-agent chemotherapy, which generates responses in just 12% of patients with short duration and severe adverse effects,” said Joanne Schindler, M.D., D.V.M., Chief Medical Officer at IMV. “These results demonstrate DPX-Survivac’s clinical potential as a well-tolerated and, possibly, more effective treatment than currently available therapies. We believe this outcome places DPX-Survivac at the forefront of a new paradigm in the treatment of ovarian cancer and other solid tumors, as a targeted T cell therapy that can achieve durable responses while maintaining quality of life.”

Updated Results from DeCidE1

All 22 patients with advanced recurrent ovarian cancer enrolled in this arm of the study were heavily pre-treated, with the median number of prior therapies greater than three.

As of February 24, 2020, 19 patients were evaluable for efficacy with six patients (31%) still receiving treatment. Key preliminary findings are outlined below:

  • 15 patients (79%) achieved disease control, defined as Stable Disease (SD) or Partial Response (PR) on target lesions
    • Tumor shrinkage of target lesions was observed in 10 patients (53%)
  • Durable clinical benefits lasting ≥6 months were observed in seven patients (37%) so far:
    • Four of these seven patients (21% of evaluable patients) achieved PR with tumor regression >30% on target lesions
    • Three stable diseases were ongoing for > 6 months (range 7-9) including -29.5% and -12% tumor regressions
    • Median duration not reached yet, with five of these seven (71%) patients still on treatment at > 6 months (range 7-10)
  • Analysis of Baseline Tumor Burden (BTB) showed durable clinical benefits across a broad range of BTB (1.5-7.7 cm) with a higher number of patients achieving benefits in BTB < 5 cm as previously observed in other arms of the study:
    • Six out 11 with BTB < 5 cm (55%) achieved clinical benefits lasting > 6 months
  • Durable clinical benefits include platinum resistant and refractory patients who previously received PARP inhibitors and bevacizumab
  • Treatment was well-tolerated, with most adverse events being Grade 1-2 reactions at the injection site

Clinical Development Plans for DPX-Survivac in Advanced Recurrent Ovarian Cancer and other cancer indications

IMV plans to take these results to the U.S. Food and Drug Administration (FDA) for a Type B meeting, to align on the design of a Phase 2b study with potential to support registration under accelerated approval in this indication.

In parallel, the Company will continue to evaluate DPX-Survivac in other tumor types. Currently, there are two actively accruing Phase 2 studies of DPX-Survivac in combination with Merck’s Keytruda®: SPiReL, an investigator-sponsored study in recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL) and a basket study across five solid tumor indications. Updated data are expected from both studies in the first half of 2020.

Conference Call and Webcast Information

IMV will host a conference call and webcast on Tuesday, February 25, 2020 at 8:00 a.m. EST to discuss the DPX-Survivac clinical results.

Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (International). Other interested parties will be able to access the live audio webcast at this link.

The Company also plans to review portions of the data at its upcoming Key Opinion Leader Symposium on Thursday, February 27, 2020 at 8:30 a.m. EST.

Both webcasts will be recorded and available on IMV website for 30 days following under “Events, Webcasts & Presentations.”

About the DeCidE1 Study

“DeCidE1” is a Phase 2 multicenter, randomized, open-label study to evaluate the safety and effectiveness of DPX-Survivac with intermittent low dose cyclophosphamide (CPA). This phase 2 arm enrolled 22 patients with recurrent, advanced platinum-sensitive and –resistant ovarian cancer. Patients received 2 subcutaneous injections of DPX-Survivac 3 weeks apart and every eight weeks thereafter, and intermittent low dose CPA one week on and one week off for up to 1 year. Paired tumor biopsies were performed prior to treatment and on treatment.

Primary endpoints of this study are overall response rate, disease control rate and safety. Secondary endpoints include cell mediated immunity, immune cell infiltration in paired biopsy samples, duration of response, time to progression, overall survival and biomarker analyses.

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of targeted immunotherapies designed to elicit antigen-specific functional, robust and sustained de novo T cell response. IMV believes this mechanism of action (MOA) is key to generating durable solid tumor regressions. DPX-Survivac consists of five unique HLA-restricted survivin peptides formulated in IMV’s proprietary DPX drug delivery platform and known to induce a cytotoxic CD8+ T cell response against survivin expressing cancer cells.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as in a combination therapy in multiple clinical studies with Merck’s Keytruda®. Connect at www.imv-inc.com.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the FDA potentially granting accelerated regulatory approval of DPX-Survivac and the timing of expected results from other DPX-Survivac’s studies with other tumor types. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful design and completion of clinical trials and the receipt and timely receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819 ext: 1042
M: (514) 617-9481 E: [email protected]

Josh Rappaport, Director, Stern IR
O: (212) 362-1200
E: [email protected]

Media

Delphine Davan, Director, Communications, IMV
M: (514) 968-1046
E: [email protected]

Source: IMV Inc.

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819 ext: 1042
M: (514) 617-9481 E: [email protected]

Josh Rappaport, Director, Stern IR
O: (212) 362-1200
E: [email protected]

Media

Delphine Davan, Director, Communications, IMV
M: (514) 968-1046
E: [email protected]

BioTalent Canada and BioNova launch new provincial life sciences job board

Feb 10, 2020 | BF2030, BioTalent Canada, News

HALIFAX, NS – February 10, 2020 – Today, BioTalent Canada and BioNova announced the launch of The PetriDish™ BioNova job board – giving companies in one of Canada’s fastest growing bio-economy hubs a platform to attract highly-skilled talent.

According to BioTalent Canada’s labour market report Mapping Potential, with over 100 life science companies, 26 research organizations and 11 post-secondary institutions, Nova Scotia is well positioned to lead innovation in Canada’s bio-economy.

“It is estimated that by 2030 the number of jobs in the life sciences sector in Nova Scotia will grow by 200%,” says Scott Moffitt, Executive Director at BioNova. “Providing a job board specific to life sciences companies in our province will help attract the talent they need to realize this potential for growth.”

As the HR partner and catalyst for growth in Canada’s bio-economy, BioTalent Canada has built relationships with employers, associations, academic institutions, governments and job seekers to address and alleviate the two key challenges still facing industry leaders – access to capital and access to talent.

“We look forward to working closer with our Silver partner, BioNova, to help their stakeholders with the necessary tools and services needed to succeed in a growing and competitive industry,” says Rob Henderson, President and CEO, BioTalent Canada. “The PetriDish BioNova will give life sciences companies in the province a dedicated platform to reach the right talent to drive their innovations, after all, without people, there can be no science.”

Modelled after BioTalent Canada’s national job board, The PetriDish BioNova will provide employers with the same benefits of narrowing their search for candidates by providing more relevant bio-economy applicants.

Members of BioNova can access free job postings to help with their recruiting needs.

For current openings or to post a job, visit BioNova.ca/Careers

About BioTalent Canada

BioTalent Canada™ is the HR partner and catalyst for growth in Canada’s bio-economy. Our engagement with employers, associations, post-secondary institutions, immigrant serving agencies and service providers has built a dynamic network that is identifying labour market needs, strengthening skills, connecting job-ready talent to industry and creating opportunities. For more information visit biotalent.ca.

About BioNova

BioNova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector. Since 1993, BioNova has been accelerating the growth of its member companies. By hosting networking and educational events, and providing connections to potential funders and business resources, BioNova helps companies succeed.  While these companies commercialize life-changing research to improve healthcare, provide healthier food, and develop clean energy solutions, BioNova advocates on behalf of the sector. BioNova champions the sector’s cluster of world-class research facilities, incubator programs, and companies who, together, bring investment and jobs to Nova Scotia. For more information visit bionova.ca.

Media inquiries:

Siobhan Williams
Director, Marketing and Communications
BioTalent Canada
613-235-1402 ext. 229
[email protected]

Shana Cristoferi
Marketing Manager
BioNova
902-421-5705 ext. 4
[email protected]